mRNA COVID-19 vaccine

ApprovedVaccine

mRNA COVID-19 vaccine is one of 88 biologic programs targeting Chronic Lymphocytic Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukemiaActive, not recruiting

Multiple SclerosisActive, not recruiting

COVID-19Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Multiple SclerosisApproved

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

mRNA COVID-19 vaccine

Novartis

Approved

4 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Activella

Tricor

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Benadryl

PParkedale

Preclinical

1 9

Rayaldee

OOrganon and Co

Preclinical

1 10

Nadroparin

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Recruiting

COVID-19

NCT05197621

Q1 2029

Phase 2Recruiting

Chronic Lymphocytic Leukemia

NCT05672355

Clinical

Trials by Indication[1]

COVID-194 trials

Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)

Completed·AAna Belen Rivas Paterna··NCT06646744·2,100 enrolled

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

Completed·—·Phase 4·NCT06038617·344 enrolled

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

Withdrawn·WWestVac Biopharma Co., Ltd.·Phase 2·NCT05465902

Show 1 more trial

The Impact of COVID-19 on Maternal and Neonatal Outcomes

Recruiting·JJohns Hopkins University··NCT05197621·300 enrolled

Pregnancy1 trial

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

Completed·—·Phase 4·NCT06503900·98 enrolled

Multiple Sclerosis1 trial

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Terminated· Novartis logo

Novartis·Phase 4·NCT04878211·24 enrolled

Chronic Lymphocytic Leukemia1 trial

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

Recruiting·—·Phase 2·NCT05672355·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for mRNA COVID-19 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA COVID-19 vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA COVID-19 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: Novartis

mRNA COVID-19 vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Trials by Indication[1]

COVID-194 trials

Pregnancy1 trial

Multiple Sclerosis1 trial

Chronic Lymphocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News